Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
Intra-Cellular Therapies NASDAQ ITCI
$72.73 0.92 1.26%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 28 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

7.00B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
6.86B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.12
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
96.29M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
1.55 %
Upcoming events Intra-Cellular Therapies All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Intra-Cellular Therapies

Stock analysis Intra-Cellular Therapies

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-50.14 35.52
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
11.84 13.63
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-43.18 17.42
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.91 0.37
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-23.62 8.90

Price change Intra-Cellular Therapies per year

22.92$ 44.80$
Min Max

Summary analysis Intra-Cellular Therapies

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Intra-Cellular Therapies

Revenue and net income Intra-Cellular Therapies

All parameters
Stock news Intra-Cellular Therapies All news
27 November 2023 в 15:36

S&P 500 Futures Fall in Premarket Trading; Intra-Cellular Therapies, GE HealthCare Techs Lag

14 June 2022 в 18:01

Intra-Cellular Therapies started at buy with $75 stock price target at UBS

5 April 2022 в 14:36

Premarket Movers: Change Healthcare, Intra-Cellular Therapies, First Solar

4 January 2022 в 15:20

Intra-Cellular Therapies Shares Fall Premarket on Planned Stock Sale >ITCI

4 January 2022 в 15:15

Intra-Cellular Therapies Shares Fall Premarket on Planned Stock Sale >ITCI

20 December 2021 в 20:00

Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up

20 December 2021 в 20:00

Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up

20 December 2021 в 15:05

Intra-Cellular Therapies Shares Up 15% After FDA Approval of Caplyta to Treat Bipolar Depression in Adults

20 December 2021 в 15:00

Intra-Cellular Therapies Shares Up 15% After FDA Approval of Caplyta to Treat Bipolar Depression in Adults

9 September 2020 в 16:21

Лидеры и аутсайдеры Уолл-cтрит: Sos Ltd, Intra-Cellular Therapies, Shiloh Industries

About company Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Address:
430 East 29th Street, New York, NY, United States, 10016
Company name: Intra-Cellular Therapies
Issuer ticker: ITCI
ISIN: US46116X1019
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2014-01-07
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.intracellulartherapies.com

On which stock exchange are Intra-Cellular Therapies (ITCI) stocks traded?

Intra-Cellular Therapies (ITCI) stocks are traded on NASDAQ.

What is the ticker of Intra-Cellular Therapies stocks (ITCI)?

The stock ticker of Intra-Cellular Therapies’s stocks or in other words, the code is ITCI. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Intra-Cellular Therapies (ITCI) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Intra-Cellular Therapies (ITCI) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Intra-Cellular Therapies (ITCI) stocks traded?

Intra-Cellular Therapies (ITCI) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Intra-Cellular Therapies (ITCI) stocks today?

The current price of Intra-Cellular Therapies stocks on 02.05.2024 is 72.73 dollars. per share.

What is the dynamics of Intra-Cellular Therapies (ITCI) stocks from the beginning of the year?

Intra-Cellular Therapies (ITCI) quotes have increased by 3.18% from the beginning of the year up to 72.73 dollars. per 1 stocks.

How much did Intra-Cellular Therapies (ITCI) stocks increase in мае 2024?

This month Intra-Cellular Therapies (ITCI) quotes have increased by 0% to 72.73 dollars. per share.

How much are Intra-Cellular Therapies (ITCI) stocks worth?

Today, on October, 02.05.2024 Intra-Cellular Therapies’s (ITCI) stocks cost 72.73 dollars..

What is the market capitalization of Intra-Cellular Therapies (ITCI)?

Capitalization is the market value of Intra-Cellular Therapies (ITCI) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 02.05.2024, the market capitalization of Intra-Cellular Therapies (ITCI) is estimated at about 7002848633 dollars.